Nexus Opens New Wisconsin Manufacturing Facility

On July 16, 2021, Nexus Pharmaceuticals celebrated the opening of the company’s new manufacturing facility in Pleasant Prairie, Wis.

Facility construction began in August 2019 and was completed in 2021. The Phase I investment of $100 million supports a new, three-story manufacturing facility with an advanced isolator system and multiple lyophilization machines. Commercial production is expected to commence in 2022. The full, multi-phase project is expected to be completed in ten years, which is approximately a $250-million investment.

In February 2021, Nexus announced its support to increase vaccine manufacturing because of the COVID-19 pandemic. With the new manufacturing capacity at the Wisconsin facility, Nexus can maintain the production of existing products and begin manufacturing vaccines without having to sacrifice the production of one drug for another.

The company hopes to bring more than 77 new high-tech manufacturing and science jobs by 2022, creating 400+ new local jobs long-term. According to a company press release, Nexus also intends to partner with local institutions to provide job training and career and research opportunities.

Source: Nexus Pharmaceuticals